Gallagher [47] investigated the effect of delaying the initiation of adjuvant trastuzumab therapy after breast cancer diagnosis on risk of relapse, OS, and RFS in a contemporary sample of patients with HER2-positive, nonmetastatic breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.